|
WO2021048423A1
|
|
Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
|
|
WO2021028587A1
|
|
Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
|
|
WO2021013746A1
|
|
Axl antibody-drug conjugates for use in treating cancer
|
|
JP2020141710A
|
|
Modulation of complement-dependent cytotoxicity through modifications of c-terminus of antibody heavy chains
|
|
JP2020198874A
|
|
Monoclonal antibody against C-MET
|
|
WO2020094744A1
|
|
Antibody formulation
|
|
TW202034958A
|
|
Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
|
|
WO2020065396A1
|
|
Axl-specific antibodies for treatment of non-small cell lung cancer
|
|
JP2020022461A
|
|
Human antibodies against human tissue factor
|
|
AU2019321442A1
|
|
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2020012038A1
|
|
Trogocytosis-mediated therapy using cd38 antibodies
|
|
AU2019300223A1
|
|
Variants of CD38 antibody and uses thereof
|
|
WO2019243626A1
|
|
Method for producing a controlled mixture of two or more different antibodies
|
|
IL267022D0
|
|
Monoclonal antibodies aganist her2
|
|
US2021107980A1
|
|
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
AU2019266203A1
|
|
Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
AU2019250443A1
|
|
AXL-specific antibodies for cancer treatment
|
|
TW202003046A
|
|
Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
|
|
WO2019175198A2
|
|
Antibodies
|
|
WO2019173523A1
|
|
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
